Jacobs Levy Equity Management Inc. decreased its stake in shares of USANA Health Sciences, Inc. (NYSE:USNA - Free Report) by 19.8% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 110,486 shares of the company's stock after selling 27,260 shares during the quarter. Jacobs Levy Equity Management Inc. owned about 0.58% of USANA Health Sciences worth $4,190,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. American Century Companies Inc. increased its stake in shares of USANA Health Sciences by 12.3% in the 2nd quarter. American Century Companies Inc. now owns 159,782 shares of the company's stock worth $7,229,000 after acquiring an additional 17,460 shares during the last quarter. Assenagon Asset Management S.A. increased its position in USANA Health Sciences by 13.5% during the third quarter. Assenagon Asset Management S.A. now owns 124,008 shares of the company's stock worth $4,702,000 after purchasing an additional 14,756 shares during the last quarter. Allspring Global Investments Holdings LLC raised its stake in USANA Health Sciences by 14,068.2% during the third quarter. Allspring Global Investments Holdings LLC now owns 38,821 shares of the company's stock worth $1,472,000 after purchasing an additional 38,547 shares during the period. Pzena Investment Management LLC boosted its holdings in USANA Health Sciences by 24.4% in the 2nd quarter. Pzena Investment Management LLC now owns 976,633 shares of the company's stock valued at $44,183,000 after purchasing an additional 191,289 shares during the last quarter. Finally, Deerfield Management Company L.P. Series C grew its stake in shares of USANA Health Sciences by 297.0% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 29,742 shares of the company's stock valued at $1,346,000 after buying an additional 22,251 shares during the period. Institutional investors and hedge funds own 54.25% of the company's stock.
USANA Health Sciences Stock Performance
Shares of USNA traded down $0.39 during midday trading on Friday, hitting $37.31. 79,128 shares of the stock were exchanged, compared to its average volume of 75,900. USANA Health Sciences, Inc. has a 52-week low of $34.15 and a 52-week high of $54.81. The stock has a fifty day simple moving average of $37.86 and a 200 day simple moving average of $41.14. The firm has a market cap of $711.13 million, a P/E ratio of 13.18, a P/E/G ratio of 1.31 and a beta of 0.89.
USANA Health Sciences (NYSE:USNA - Get Free Report) last posted its quarterly earnings data on Tuesday, October 22nd. The company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.49 by $0.07. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. The business had revenue of $200.22 million during the quarter, compared to analyst estimates of $208.45 million. During the same quarter last year, the firm posted $0.59 earnings per share. As a group, equities research analysts forecast that USANA Health Sciences, Inc. will post 2.45 EPS for the current fiscal year.
Insider Activity
In other USANA Health Sciences news, Director Gilbert A. Fuller sold 675 shares of the firm's stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $37.71, for a total transaction of $25,454.25. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 0.33% of the company's stock.
Analyst Ratings Changes
Separately, DA Davidson reduced their price target on shares of USANA Health Sciences from $38.00 to $35.00 and set a "neutral" rating on the stock in a research report on Wednesday, October 23rd.
Get Our Latest Research Report on USNA
USANA Health Sciences Profile
(
Free Report)
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.
See Also
Before you consider USANA Health Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and USANA Health Sciences wasn't on the list.
While USANA Health Sciences currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.